Use your browser's back button to choose another title or click here for a New Search.


How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

 Comments?

 

Bookmark and Share

 

Using Medication-Assisted Treatment for Substance Use Disorders: Evidence of Barriers and Facilitators of Implementation.

Addictive Behaviors 2011;36(6):584-589. [doi: 10.1016/j.addbeh.2011.01.032]

Paul M. Roman, PhD (University of Georgia), Amanda J. Abraham, PhD (University of Georgia), Hannah K. Knudsen, PhD (University of Kentucky).

The use of medications to treat substance use disorders (SUDs) has emerged as a potentially central part of the treatment armamentarium. In this paper from the National Treatment Center Study, the authors present data from several recent US national surveys (including two waves of onsite data collected from CTPs participating in the National Drug Abuse Treatment Clinical Trials Network (CTN)) showing that despite the clinical promise of these medications, there has been limited adoption of pharmacotherapies in the treatment of SUDs. The data reveal variable patterns of use of disulfiram, buprenorphine, tablet naltrexone, acamprosate, and injectable naltrexone. After examining the environmental and institutional context for the adoption of pharmacotherapies, the specific organizational facilitators and barriers of medication adoption are considered. The paper concludes with a discussion of the minimal clinical and administrative guidance available to enhance adoption, the lack of client and consumer knowledge of medications that puts a brake on their adoption and availability, and the difficulties that must be surmounted in bringing new medications to market. This article describes a dysfunctional and perhaps tragic disconnect between science and practice that cannot be closed by the protracted rhetoric about the importance of the adoption of EBPs. Federal agencies and private organizations can invest in pharmacological research, but making those medications available to patients is ultimately a step governed by decisions among investors in the marketplace, the primary issue being ultimate profitability. Given the level of adoption in the data presented here, to say nothing about full-scale implementation, the commercial attractiveness of new SUDs medications is definitely open to question. (Article (Peer-Reviewed), PDF, English, 2011)

Keywords: Acamprosate | Adoption of interventions | Buprenorphine | Dissemination | Disulfiram | Evidence-based treatment | Naltrexone | National Treatment Center Study (NTCS) | Pharmacological therapy | Addictive Behaviors (journal)

Document No: 664, PMID: 21377275, PMCID: PMC3087632.

Submitted by CTN Dissemination Librarians, 3/23/2011.

AUTHORS SEARCH LINK
Abraham, Amanda J. mail
Knudsen, Hannah K. mail
Roman, Paul M. mail


dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 6/2012 -- http://ctndisseminationlibrary.org/display/664.htm
info@ctndisseminationlibrary.org
dark blue line